LEXINGTON, Mass., Sept. 20, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage
biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to endogenous
aldehyde toxicity, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of
Aldeyra, will present at the Annual Cantor Fitzgerald Global
Healthcare Conference on Wednesday,
September 27, 2017.
Event: Annual Cantor Fitzgerald Global Healthcare
Conference
Date: Wednesday, September 27,
2017
Time: 2:15 PM ET
Location: The InterContinental New York Barclay Hotel in
New York City
About Aldeyra
Therapeutics
Aldeyra Therapeutics, Inc. is
a biotechnology company devoted to improving lives by inventing,
developing and commercializing products that treat diseases thought
to be related to endogenous aldehydes, a naturally occurring class
of pro-inflammatory and toxic molecules. Aldeyra's lead
product candidate, ADX-102, is an aldehyde trap in development as
topical eye drops for the treatment of ocular inflammation. ADX-102
has now been tested in over 250 patients in Phase 2 clinical trials
in dry eye disease, allergic conjunctivitis, and noninfectious
anterior uveitis. A dermatologic form of ADX-102 is in late-stage
clinical development for the treatment of ichthyosis due to
Sjögren-Larsson Syndrome, an inborn error of aldehyde metabolism.
ADX-102 has not been approved for sale in the U.S. or
elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-annual-cantor-fitzgerald-global-healthcare-conference-300522673.html
SOURCE Aldeyra Therapeutics, Inc.